EA treatment might regulate lncRNA-XR_002789763.1/miR-342-5p axis and activate the mitophagy-related PINK1/Parkin signaling pathway, and promote Mfn2 ubiquitination, thereby alleviating RGC damage and delaying myopia progression. The gene discussed is PRKN; the disease is myopia.